44
Participants
Start Date
July 5, 2016
Primary Completion Date
August 26, 2020
Study Completion Date
August 26, 2020
Zanubrutinib
Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.
Beijing Cancer Hospital, Beijing
Jiangsu Province Hospital, Nanjing
Institute of Hematology and Hospital of Blood Disease, Tianjin
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan
Lead Sponsor
BeiGene
INDUSTRY